GlassScriptPhysician profile
Jay Mukesh Patel
NPI 1619331303
$10,978.66
in general payments reported to CMS, 2019-2025
16 companies · $3,087 in 2025
The $3,087 reported for 2025 was more than what 88% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $140 · 2020: $20.74 · 2021: $75.00 · 2022: $1,647 · 2023: $2,741 · 2024: $3,268 · 2025: $3,087.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,094 · Travel and Lodging: $1,126 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $600 · Consulting Fee: $150 · Grant: $125.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,094.12 |
| Travel and Lodging | $1,126.40 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $600.00 |
| Consulting Fee | $150.00 |
| Grant | $125.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $4,151.68 | 2022-2025 | Corevalve Evolut R, Symplicity G3, Onyx Frontier |
| Shockwave Medical, INC | $1,913.58 | 2023-2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Intravascular Lithotripsy (Ivl) System With The Shockwave C2+ Coronary |
| Abiomed | $1,636.79 | 2022-2025 | Impella |
| Heartflow, INC. | $1,269.76 | 2024-2025 | |
| Boston Scientific Corporation | $1,053.14 | 2022-2025 | Emerge Push, Comet, Synergy |
| Pfizer INC. | $256.88 | 2019-2023 | |
| Esperion Therapeutics, INC. | $124.72 | 2023 | Nexlizet, Nexletol |
| Abbott Laboratories | $113.72 | 2023 | Diamondback Coronary, Cardiomems |
| Cardiva Medical, INC. | $101.42 | 2023-2024 | Cardiva Vascade Mvp Vvcs 6-12f, Cardiva Vascade 6/7f Vcs |
| Philips North America LLC | $92.30 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $75.00 | 2021 | |
| Penumbra, INC. | $63.06 | 2023 | Indigo System |
| Amgen INC. | $49.33 | 2025 | Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $41.43 | 2025 | Jardiance |
| Edwards Lifesciences Corporation | $18.85 | 2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teleflex LLC | $17.00 | 2025 | Guideliner |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jay Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.